Inspire Medical Systems, Inc. (NYSE:INSP) Shares Sold by Arizona State Retirement System

Arizona State Retirement System lessened its stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 1.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 8,201 shares of the company’s stock after selling 105 shares during the period. Arizona State Retirement System’s holdings in Inspire Medical Systems were worth $1,668,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Commonwealth Equity Services LLC grew its holdings in shares of Inspire Medical Systems by 0.5% during the first quarter. Commonwealth Equity Services LLC now owns 6,774 shares of the company’s stock valued at $1,585,000 after buying an additional 36 shares during the last quarter. Metropolitan Life Insurance Co NY lifted its position in Inspire Medical Systems by 2.3% during the 4th quarter. Metropolitan Life Insurance Co NY now owns 1,734 shares of the company’s stock worth $437,000 after acquiring an additional 39 shares during the period. Mercer Global Advisors Inc. ADV grew its stake in Inspire Medical Systems by 3.9% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 1,122 shares of the company’s stock valued at $364,000 after purchasing an additional 42 shares during the last quarter. Y Intercept Hong Kong Ltd increased its holdings in shares of Inspire Medical Systems by 3.7% in the second quarter. Y Intercept Hong Kong Ltd now owns 1,200 shares of the company’s stock valued at $390,000 after purchasing an additional 43 shares during the period. Finally, Pathstone Family Office LLC raised its stake in shares of Inspire Medical Systems by 2.7% in the third quarter. Pathstone Family Office LLC now owns 2,273 shares of the company’s stock worth $403,000 after purchasing an additional 59 shares during the last quarter. Institutional investors and hedge funds own 94.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Mizuho reiterated a “buy” rating and issued a $250.00 target price on shares of Inspire Medical Systems in a research report on Wednesday, March 27th. Morgan Stanley started coverage on shares of Inspire Medical Systems in a research note on Tuesday, March 19th. They issued an “overweight” rating and a $250.00 price objective on the stock. Jefferies Financial Group assumed coverage on shares of Inspire Medical Systems in a research report on Friday, January 19th. They set a “buy” rating and a $245.00 target price for the company. Stifel Nicolaus reaffirmed a “hold” rating and set a $210.00 price target on shares of Inspire Medical Systems in a research report on Tuesday, January 2nd. Finally, Truist Financial reiterated a “buy” rating and set a $280.00 price objective on shares of Inspire Medical Systems in a research note on Wednesday, March 20th. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, Inspire Medical Systems presently has a consensus rating of “Moderate Buy” and a consensus price target of $271.29.

Inspire Medical Systems Trading Down 0.3 %

Shares of INSP opened at $231.64 on Friday. The firm has a market cap of $7.02 billion, a P/E ratio of -313.03 and a beta of 1.37. Inspire Medical Systems, Inc. has a 12 month low of $123.27 and a 12 month high of $330.00. The stock’s 50 day moving average is $201.18 and its two-hundred day moving average is $182.72.

Inspire Medical Systems (NYSE:INSP) last announced its earnings results on Tuesday, February 6th. The company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.53. The firm had revenue of $192.51 million for the quarter, compared to analyst estimates of $186.75 million. Inspire Medical Systems had a negative return on equity of 3.93% and a negative net margin of 3.39%. The business’s revenue was up 39.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.10 EPS. Equities research analysts forecast that Inspire Medical Systems, Inc. will post -0.35 EPS for the current year.

Insider Buying and Selling at Inspire Medical Systems

In other news, insider Randy Ban sold 12,230 shares of the business’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $185.37, for a total transaction of $2,267,075.10. Following the completion of the sale, the insider now owns 3,029 shares of the company’s stock, valued at $561,485.73. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Randy Ban sold 12,230 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $185.37, for a total value of $2,267,075.10. Following the transaction, the insider now owns 3,029 shares in the company, valued at $561,485.73. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jerry C. Griffin sold 554 shares of Inspire Medical Systems stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $198.05, for a total value of $109,719.70. Following the completion of the sale, the director now directly owns 9,744 shares in the company, valued at $1,929,799.20. The disclosure for this sale can be found here. Insiders have sold a total of 61,371 shares of company stock valued at $12,213,828 over the last ninety days. Corporate insiders own 4.10% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.